Optimizing Multidisciplinary Care for ESR1-Mutated Breast Cancer: Strategies and Future Directions
Panelists discuss strategies for medication adherence and patient education, emphasizing the importance of proactive communication and support from the entire health care team.
Video content above is prompted by the following:
The final segment focuses on the importance of team-based care and strategies for medication adherence in treating patients with metastatic breast cancer. Rikal emphasizes patient education as a critical component of treatment success, highlighting the need to thoroughly explain potential adverse effects and management strategies. The goal is to prevent unnecessary treatment interruptions that could compromise patient outcomes, such as unplanned drug holidays that might lead to disease progression.
The panelists discuss the multidisciplinary approach to patient care, including the role of triage nurses and support staff in managing patient experiences. They stress the importance of comprehensive education about medication management, adverse effect recognition, and when to seek medical intervention. The discussion also touches on the challenges of medication access, withTraina noting the significance of financial support programs and assistance in navigating prior authorization processes.
Looking forward, the panelists express excitement about the rapidly evolving landscape of breast cancer treatment. They anticipate continued advancements in selective estrogen receptor degraders, combination therapies, and targeted options. The panel is particularly optimistic about potential developments in both metastatic and curative settings, drawing parallels to how CDK 4/6 inhibitors transformed breast cancer treatment. Their collective outlook emphasizes the potential for improved patient outcomes through continued research and personalized treatment approaches.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Addition of Inavolisib Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer
May 23rd 2025The phase 3 INAVO120 trial showed that overall survival significantly improved with the addition of inavolisib to palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative, endocrine-resistant advanced breast cancer.
